ERJ Open Research (Mar 2023)

COVID-19 and its continuing burden after 12 months: a longitudinal observational prospective multicentre trial

  • Sabina Sahanic,
  • Piotr Tymoszuk,
  • Anna K. Luger,
  • Katharina Hüfner,
  • Anna Boehm,
  • Alex Pizzini,
  • Christoph Schwabl,
  • Sabine Koppelstätter,
  • Katharina Kurz,
  • Malte Asshoff,
  • Birgit Mosheimer-Feistritzer,
  • Maximilian Coen,
  • Bernhard Pfeifer,
  • Verena Rass,
  • Alexander Egger,
  • Gregor Hörmann,
  • Barbara Sperner-Unterweger,
  • Raimund Helbok,
  • Ewald Wöll,
  • Günter Weiss,
  • Gerlig Widmann,
  • Ivan Tancevski,
  • Thomas Sonnweber,
  • Judith Löffler-Ragg

DOI
https://doi.org/10.1183/23120541.00317-2022
Journal volume & issue
Vol. 9, no. 2

Abstract

Read online

Background Recovery trajectories from coronavirus disease 2019 (COVID-19) call for longitudinal investigation. We aimed to characterise the kinetics and status of clinical, cardiopulmonary and mental health recovery up to 1 year following COVID-19. Methods Clinical evaluation, lung function testing (LFT), chest computed tomography (CT) and transthoracic echocardiography were conducted at 2, 3, 6 and 12 months after disease onset. Submaximal exercise capacity, mental health status and quality of life were assessed at 12 months. Recovery kinetics and patterns were investigated by mixed-effect logistic modelling, correlation and clustering analyses. Risk of persistent symptoms and cardiopulmonary abnormalities at the 1-year follow-up were modelled by logistic regression. Findings Out of 145 CovILD study participants, 108 (74.5%) completed the 1-year follow-up (median age 56.5 years; 59.3% male; 24% intensive care unit patients). Comorbidities were present in 75% (n=81). Key outcome measures plateaued after 180 days. At 12 months, persistent symptoms were found in 65% of participants; 33% suffered from LFT impairment; 51% showed CT abnormalities; and 63% had low-grade diastolic dysfunction. Main risk factors for cardiopulmonary impairment included pro-inflammatory and immunological biomarkers at early visits. In addition, we deciphered three recovery clusters separating almost complete recovery from patients with post-acute inflammatory profile and an enrichment in cardiopulmonary residuals from a female-dominated post-COVID-19 syndrome with reduced mental health status. Conclusion 1 year after COVID-19, the burden of persistent symptoms, impaired lung function, radiological abnormalities remains high in our study population. Yet, three recovery trajectories are emerging, ranging from almost complete recovery to post-COVID-19 syndrome with impaired mental health.